RESPONSE OF THE DUNNING R3327H PROSTATIC ADENOCARCINOMA TO RADIATION AND VARIOUS CHEMOTHERAPEUTIC DRUGS
- 1 January 1982
- journal article
- research article
- Vol. 66 (10) , 1837-1843
Abstract
Dunning [rat] R3327H prostatic adenocarcinoma was bilaterally transplanted in the flanks of animals at the Papanicolaou Institute in Miami [Florida, USA]; the animals were received at the Cross Cancer Institute (Edmonton, Alberta, Canada) each month. The animal flanks were palpated weekly, when tumor volumes reached a size of .apprx. 300 mm3 the animals were randomized into treatment groups for the assessment of various therapies. Tumor volumes were determined each week before and after various treatments; tumor growth was compared to that in untreated controls. Ionizing radiation at relatively small single doses completely inhibits tumor growth for a period of up to 6 mo. Some interesting characteristics of this radiation-induced growth arrest are that tumors do not die and shrink away as with some other tumor models but remain static in size and show histologic evidence of viable tumor cells. The hypoxic cell radiosensitizer misonidazole potentiates radiation response in this tumor model. Cisplatin, vincristine, etoposide and estramustine phosphate administered in drug doses approaching their toxic limits have a partial effect on tumor growth.This publication has 6 references indexed in Scilit:
- Investigation of different combinations of estrogen therapy and radiation therapy on prostatic adenocarcinoma (R-3327)Urology, 1980
- Studies on the Toxicity and Radiosensitizing Ability of Misonidazole under Conditions of Prolonged IncubationRadiation Research, 1978
- The significance of needle biopsy after irradiation for stage c adenocarcinoma of the prostateCancer, 1977
- Rdiation therapy in the management of localized carcinoma of the prostate.A preliminary reportCancer, 1977
- SUCCESS AND FAILURE IN TREATMENT OF SOLID TUMORS .I. EFFECTS OF CYCLOPHOSPHAMIDE (NSC-26271) ON PRIMARY AND METASTATIC PLASMACYTOMA IN HAMSTER1968
- EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS .4. HOST WEIGHT LOSS AS IT RELATES TO FALSE POSITIVES IN DRUG EVALUATION1961